Comparative study on the efficacy of Yiweining and Gestrinone for post-operational treatment of stage III endometriosis.
OBJECTIVE
To observe the clinical efficacy and safety of Yiweining (YWN) and gestrinone (GT) in treating post-operational patients of stage III endometriosis (EM-III).


METHODS
Fifty-two patients of EM-III after operation were randomly assigned into three groups, the YWN group (20 patients) was treated through oral intake of YWN 200 ml, twice a day; the GT group (19 patients) treated with gestrinone 2.5 mg, twice every week, with the medication starting from the 7th post-operational day and lasting for 6 months. The control group (13 patients) was untreated. Six months was one therapeutic course, and follow-up study was carried out in the 6 - 30 months after the end of the medication.


RESULTS
The recurrence rate in the YWN group and the GT group were 5.0% and 5.3% respectively, showing insignificant difference between the two groups, but they were lower than that in the control group (30.7%, P < 0.05). Besides, the adverse reaction rate in the YWN group was lower than that in the GT group (10.0% vs 31.6%, P < 0.05).


CONCLUSIONS
Application of YWN to prevent the post-operational recurrence of endometriosis is effective and safe, and its efficacy is similar to that of GT.
Yang
Dong-xia
DX
Department of Gynecology, Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, China.
Ma
Wen-guang
WG
Qu
Fan
F
Ma
Bao-zhang
BZ
D000284:Administration, Oral; D000328:Adult; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage* / Q000009:adverse effects; D004715:Endometriosis / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D005867:Gestrinone / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D011183:Postoperative Complications / Q000188:drug therapy / Q000517:prevention & control; D011247:Pregnancy; D018873:Pregnancy Rate; D011372:Progestins / Q000008:administration & dosage* / Q000009:adverse effects; D055502:Secondary Prevention; D016896:Treatment Outcome
D004365:Drugs, Chinese Herbal; D011372:Progestins; D005867:Gestrinone